Investigating the weaknesses in small cell lung cancer to develop new treatments
Official title: Understanding and targeting unique vulnerabilities governing G1/S transition and replication stress in small cell lung cancer
Funded at Temple Univ of the Commonwealth · NIH-11236017 · Data updated 2026-11-12
This study is looking at small cell lung cancer to understand how a protein called LMNA affects the cancer cells and causes problems with their DNA, with the hope of finding new ways to treat patients more effectively.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Temple Univ of the Commonwealth NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | January 1, 2025 |
| Project end | December 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $216,972 |
| NIH project number | 4R00CA277246-02 |
| Project ID | NIH-11236017 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with small cell lung cancer, particularly those with advanced disease.
✕Less likely to help
Patients with other types of lung cancer or those who are not diagnosed with cancer may not benefit from this research.
What this research studies
This research focuses on small cell lung cancer (SCLC), a highly aggressive form of cancer with a poor prognosis. The study aims to understand the mechanisms behind increased replication stress in SCLC cells, particularly the role of a protein called LMNA. By exploring how low levels of LMNA contribute to DNA damage and genomic instability, the researchers hope to identify new therapeutic targets. The approach includes using specific agents to stabilize R-loops and inhibit LMNA, potentially leading to more effective treatments for patients.
Why it matters
Potential benefit: If successful, this research could lead to novel therapies that significantly improve survival rates for patients with small cell lung cancer.
How similar studies have gone: Previous research has shown promise in targeting replication stress in cancer, suggesting that this approach may yield beneficial results.
Where this research is happening
-
Temple Univ of the Commonwealth
Philadelphia, United States Active
Researchers
- Principal investigator: Schultz, Christopher William — Temple Univ of the Commonwealth
- Study coordinator: Schultz, Christopher William
Related research
Other NIH-funded projects on the same topics.
-
ABL kinase signaling and DNA collisions in small cell lung cancer
A drug target study in small cell lung cancer explores how blocking ABL kinase affects conflicts between transcription and DNA replication, which could influence tumor growth and survival.
-
XRN1 as a potential therapy target in lung cancer
A scientist-led program will study a cellular gene called XRN1 to see if turning it off can help treat non-small cell lung cancer.
-
Intermittent fasting with PD-1 inhibitors for non-small cell lung cancer
This grant tests whether a fasting-mimicking diet can boost the effectiveness of PD-1 inhibitors for people with non-small cell lung cancer.
-
Targeting STRAP to curb NSCLC spread with nanoparticle therapy
Aimed at non-small cell lung cancer, this grant tests how blocking a protein called STRAP with nanoparticles could slow cancer spread and make chemotherapy work better.
-
Modeling tumor differences to guide new treatments for resistant small cell lung cancer
A study aims to understand why some small cell lung cancer tumors resist treatment and use those insights to develop new targeted therapies.
-
TP53-mutant NSCLC: how epigenetic viral mimicry could boost immune therapy
A research grant exploring how p53 mutations in non-small cell lung cancer affect responses to a viral mimicry-based epigenetic therapy, with the goal of improving immune therapy outcomes for patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.